Table 6.
Percent or absolute change from baseline to final visit in key clinical chemistry, hematology and hemodynamic parameters
| Parameter | Oral TU (n) | Topical T (n) |
|---|---|---|
| Alanine aminotransferase (U/L) | −5.38 ± 31.72% (159) | −6.09 ± 30.57% (51) |
| Alkaline phosphatase (U/L) | −14.10 ± 11.84% (162) | −4.83 ± 19.81% (53) |
| Aspartate amino transferase (U/L) | 2.74 ± 39.07% (159) | −0.74 ± 29.64% (51) |
| Bilirubin (umol/L) | 0.41 ± 50.3% (162) | 7.8 ± 41.7% (53) |
| Total cholesterol (mmol/L) | −4.29 ± 15.28% (156) | −5.14 ± 12.13% (51) |
| HDLc (mmol/L) | −13.91 ± 15.67% (162) | −3.39 ± 16.06% (53) |
| LDLc (mmol/L) | 5.95 ± 26.04% (162) | −2.14 ± 17.71% (53) |
| Triglycerides (mmol/L) | 12.99 ± 46.23% (162) | 8.07 ± 35.08% (53) |
| Prostate specific antigen (ug/L) | 0.17 ± 0.48 (161) | 0.26 ± 0.38 (51) |
| Hematocrit (L/L) | 5.97 ± 7.46% (160) | 4.73 ± 6.65% (53) |
| Systolic BP | ||
| Cuff (mmHg) | 2.8 ± 11.8 (162) | 1.8 ± 10.8 (54) |
| ABPM (mmHg) | 4.9 ± 8.7 (162) | 0.2 ± 9.4 (45) |
| Diastolic BP (mmHg) | 0.6 ± 8.3 (162) | 0.6 ± 7.4 (54) |
| Heart rate (beats/min) | 2.1 ± 9.1 (162) | 2.1 ± 7.9 (54) |